search
Back to results

Phase I Pharmacokinetic Study (BF-BLOCK) (BF-BLOCK)

Primary Purpose

Asthma

Status
Completed
Phase
Phase 1
Locations
Finland
Study Type
Interventional
Intervention
Budesonide/formoterol capsule.
Budesonide/formoterol capsule for oral adm.
Sponsored by
Orion Corporation, Orion Pharma
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring Asthma

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy males and females aged 18-60 years.
  2. Normal weight at least 50 kg.

Exclusion Criteria:

  1. Evidence of a clinically significant cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolic-endocrine, neurological or psychiatric disease.
  2. Any clinically significant abnormal laboratory value or physical finding that may interfere with the interpretation of study results or constitute a health risk for the subject if he/she takes part in the study.
  3. Any condition requiring concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during the study.
  4. Known hypersensitivity to the active substance(s) or the excipients of the drug.
  5. Pregnant or lactating females.

Sites / Locations

  • Clinical Reseach Services Turku (CRST)

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Treatment A

Treatment B

Arm Description

Budesonide/formoterol capsule (Orion Pharma) for oral administration.

Budesonide/formoterol capsule (Orion Pharma) for oral administration.

Outcomes

Primary Outcome Measures

The evaluation of primary pharmacokinetic variable AUCt
The evaluation of primary pharmacokinetic variable AUCt of this study will be based on statistical methods appropriate for crossover design.

Secondary Outcome Measures

Pharmacokinetic variables
Cmax
Pharmacokinetic variable
tmax

Full Information

First Posted
August 23, 2011
Last Updated
October 20, 2011
Sponsor
Orion Corporation, Orion Pharma
search

1. Study Identification

Unique Protocol Identification Number
NCT01423305
Brief Title
Phase I Pharmacokinetic Study (BF-BLOCK)
Acronym
BF-BLOCK
Official Title
Effect of Charcoal on Gastrointestinal Absorption of Budesonide and Formoterol
Study Type
Interventional

2. Study Status

Record Verification Date
October 2011
Overall Recruitment Status
Completed
Study Start Date
August 2011 (undefined)
Primary Completion Date
October 2011 (Actual)
Study Completion Date
October 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Orion Corporation, Orion Pharma

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of the study is to assess if charcoal prevents the absorption of budesonide and formoterol via GI track. The assessment will be based on comparing the pharmacokinetic parameter area under the concentration-time curve.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Asthma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment A
Arm Type
Experimental
Arm Description
Budesonide/formoterol capsule (Orion Pharma) for oral administration.
Arm Title
Treatment B
Arm Type
Experimental
Arm Description
Budesonide/formoterol capsule (Orion Pharma) for oral administration.
Intervention Type
Drug
Intervention Name(s)
Budesonide/formoterol capsule.
Intervention Description
Oral administration with concomitant charcoal.
Intervention Type
Drug
Intervention Name(s)
Budesonide/formoterol capsule for oral adm.
Intervention Description
Oral administration without concomitant charcoal.
Primary Outcome Measure Information:
Title
The evaluation of primary pharmacokinetic variable AUCt
Description
The evaluation of primary pharmacokinetic variable AUCt of this study will be based on statistical methods appropriate for crossover design.
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Pharmacokinetic variables
Description
Cmax
Time Frame
4 weeks
Title
Pharmacokinetic variable
Description
tmax
Time Frame
4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy males and females aged 18-60 years. Normal weight at least 50 kg. Exclusion Criteria: Evidence of a clinically significant cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolic-endocrine, neurological or psychiatric disease. Any clinically significant abnormal laboratory value or physical finding that may interfere with the interpretation of study results or constitute a health risk for the subject if he/she takes part in the study. Any condition requiring concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during the study. Known hypersensitivity to the active substance(s) or the excipients of the drug. Pregnant or lactating females.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mika Scheinin, M.D.Ph.D
Organizational Affiliation
Clinical Research Services Turku Finland
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinical Reseach Services Turku (CRST)
City
Turku
ZIP/Postal Code
20520
Country
Finland

12. IPD Sharing Statement

Learn more about this trial

Phase I Pharmacokinetic Study (BF-BLOCK)

We'll reach out to this number within 24 hrs